AMNEAL PHARMACEUTICALS INC CLASS A (AMRX)
Sector: Health Care
2026 Annual Meeting Analysis
AMNEAL PHARMACEUTICALS INC CLASS A · Meeting: May 6, 2026
Directors FOR
10
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Independent director with strong regulatory expertise; TSR trigger does not apply as AMRX's 3-year return of +701.3% exceeds the ^RUT (Russell 2000) benchmark by +656.7 percentage points, well above the 65-point threshold that would need to be exceeded to trigger a vote against, and no overboarding, attendance, or other policy concerns are present.
Experienced pharmaceutical executive and director; TSR trigger does not apply given AMRX's exceptional outperformance of the ^RUT (Russell 2000) over three years, and no overboarding, attendance, or other policy concerns are identified.
Brings deep global pharmaceutical and healthcare leadership experience; TSR trigger does not apply given AMRX's 3-year return of +701.3% vastly exceeds the ^RUT (Russell 2000) by +656.7 percentage points, and no other policy concerns are present.
Former PricewaterhouseCoopers Senior Assurance Partner with 35+ years of financial expertise, designated as Audit Committee financial expert; TSR trigger does not apply and no other policy concerns are present.
Independent Chairman with extensive life sciences and public company executive experience; TSR trigger does not apply given exceptional stock outperformance, and while he holds multiple outside board seats the disclosed seats do not reach the four-board overboarding threshold.
Compensation Committee Chair with strong private equity and corporate leadership background; TSR trigger does not apply and no overboarding, attendance, or other policy concerns are present.
Co-CEO and co-founder who has led six consecutive years of revenue growth; as an executive director he is subject to the same TSR trigger as other directors, but the trigger does not apply because AMRX's 3-year return of +701.3% outperforms the ^RUT (Russell 2000) by +656.7 percentage points, well above the 65-point threshold, and no other policy concerns arise.
Co-CEO, President, and co-founder with a strong operational track record; as an executive director he is subject to the same TSR trigger, but it does not apply given AMRX's exceptional outperformance of the ^RUT (Russell 2000) over three years, and no other policy concerns are present.
Managing Director of Tarsadia Investments with deep finance and healthcare investing experience; TSR trigger does not apply and no overboarding, attendance, or independence concerns are present, though shareholders should note he is an Amneal Group Director representing the controlling shareholder group.
Former Teva Pharmaceutical CEO with broad pharmaceutical industry leadership experience; TSR trigger does not apply and no overboarding, attendance, or other policy concerns are identified.
All ten director nominees receive a FOR vote determination. The company's 3-year price return of +701.3% dramatically outperforms the ^RUT (Russell 2000) benchmark by +656.7 percentage points, which is far in excess of the 65-point threshold that would need to be surpassed to trigger votes against directors — meaning the TSR trigger does not apply to any director. No directors are flagged for overboarding, poor attendance, lack of relevant qualifications, or independence concerns. Two directors (Chintu Patel and Chirag Patel) serve as Co-CEOs but are evaluated on the same TSR standard and pass. Gautam Patel represents the Amneal Group controlling shareholder, which shareholders should be aware of as a governance context.
Say on Pay
✓ FORCEO
Chintu Patel
Total Comp
$8,730,545
Prior Support
99.4%%
The CEO (Chintu Patel) received total compensation of approximately $8.73 million in 2025, which is reasonable for a co-CEO of a nearly $4 billion market cap healthcare company that delivered six consecutive years of revenue growth, 8% revenue growth in 2025, and stock price appreciation far exceeding the ^RUT (Russell 2000) benchmark. The pay program is well-structured: a significant portion of total pay is variable and performance-based, including performance stock awards tied to multi-year absolute stock price growth targets and annual cash bonuses tied to adjusted EBITDA, and the 2023 performance stock awards paid out at 200% of target reflecting 594% actual stock price growth against a 300% maximum goal. The company received 99.4% shareholder support on last year's Say on Pay vote, a clawback policy meeting Nasdaq requirements is in place, and no flags related to pay level, pay mix adequacy, or pay-for-performance alignment are triggered.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
N/A
Non-Audit Fees
N/A
Ernst & Young LLP is a Big 4 firm appropriate for a company of Amneal's size and complexity. The proxy filing does not include an auditor fee table with specific audit and non-audit fee figures, so the non-audit fee ratio trigger cannot be evaluated — per policy, when fee data is not available the default vote is FOR. Auditor tenure is not disclosed in the proxy, and per policy the tenure trigger requires confirmed data to fire, so no tenure concern is raised. No material financial restatements attributable to audit failure are disclosed.
Overall Assessment
The 2026 Amneal Pharmaceuticals annual meeting presents a clean ballot with strong support warranted across all three standard proposals. The company's exceptional stock performance — a 3-year return of +701.3% versus the ^RUT (Russell 2000) benchmark's +44.6% — clears all director TSR triggers, executive compensation is well-structured with meaningful performance conditions and 99.4% prior-year shareholder support, and Ernst & Young LLP is an appropriate Big 4 auditor for the company's size and complexity. No stockholder proposals appear on this year's ballot.
Compensation Peer Group
1 companies disclosed in 2026 proxy filing